Biomedical industry is China's strategic emerging industry key areas, at present, China's biomedical industry development has entered a new stage, in response to the new situation changes, many places are issuing favorable policies, more targeted support for enterprises, to promote the biomedical industry to become bigger and stronger
.
The output value of biomedical manufacturing continues to grow, and the field will usher in a favorable (Image source: Pharmaceutical Network)
Under favorable policies, the output value of biomedical manufacturing will continue to break through
For example, the "Shanghai Pudong New Area Provisions on Promoting the Construction of Zhangjiang Biomedical Industry Innovation Highland" appropriately changes the entry and exit system for special biomedical goods and R&D items, further promotes customs clearance facilitation, and at the same time, optimizes the entrusted production system of pharmaceutical manufacturers, and promotes enterprises to quickly stabilize production and expand capacity
.
In this regard, the Standing Committee of the People's Congress of Pudong New Area revealed that the "biomedicine" regulations will provide a legal guarantee for the breakthrough of Pudong biomedical industry in terms of innovation level, industrial scale, industrial ecology and industrial cluster effect, and it is expected that the scale of Pudong's biomedical industry will reach 400 billion yuan in 2024, and the output value of biomedical manufacturing industry will exceed 100 billion yuan
.
Prior to this, the Chongqing Municipal Economic Information Commission issued the "14th Five-Year Plan for Chongqing Biomedical Industry" (hereinafter referred to as the "Plan"), pointing out that during the "14th Five-Year Plan" period, Chongqing's pharmaceutical industry will further adapt to the profound changes in the development environment and development conditions, and gradually enter a new stage
of high-quality development with continuous improvement of innovation capabilities and continuous upgrading of the modernization level of the industrial chain.
Among them, the "Plan" also clearly states that by the end of the "14th Five-Year Plan", the scale of Chongqing's biomedical industry will strive to exceed 200 billion yuan
.
In addition, in the "Implementation Plan for the Construction of Biomedical Industry Innovation Cluster" issued by Suzhou, the main goal is also mentioned that by 2023, strive to exceed 330 billion yuan in industrial scale, 270 billion yuan in output value, introduce more than 5 new talents (teams) or major innovation teams, and annually more than 5 newly declared and marketed drugs, more than 100 newly declared and listed Class II and Class III medical device products, and form a cluster of industrial innovation elements
.
Favorable to the development of the industry, the development of the biopharmaceutical equipment industry will usher in more opportunities
Judging from the many favorable policies for the development of the biomedical industry issued so far, the biomedical industry has become a key industry for development in various places, and the number and content of policies are also changing
with the development direction of the industry.
Under the favorable policy, it is expected that the development of China's biomedical manufacturing industry will accelerate, and the market scale will usher in more new breakthroughs
.
It is worth noting that due to the favorable development of the industry, the market demand for biopharmaceutical equipment in China is expected to continue to expand
.
The industry believes that in this context, the localization demand for upstream key equipment and consumables will also be more urgent, which is undoubtedly expected to bring more opportunities
to the head enterprises with strength in the biomedical equipment industry.
It is understood that in the context of the rapid development of the biomedical industry, in fact, the performance growth of some enterprises has been very obvious
.
In the first half of 2022, Dongfulong's performance maintained a growth trend, of which bioengineering and consumables entered the volume stage, and the contract debt in the first half of the year reached 3.
9 billion yuan, a year-on-year increase of 41%.
It is worth mentioning that at present, Chutian Technology, Canaan Technology, Dongfulong, etc.
are full of confidence in the future development of the biological sector, and are still increasing the layout of the biological sector
.
For example, on October 17, 2022, Dongfulong issued an announcement that the company's proposed additional capital of no more than 3.
2 billion yuan was approved, and the funds raised this time, after deducting the issuance expenses, were mainly used to increase the production capacity of biopharmaceutical equipment and supplement working capital
.
At present, under the background of increasing investment and accelerating R&D and innovation, pharmaceutical equipment enterprises are constantly showing their achievements in the field of biomedicine
.
It is reported that the disposable frozen liquid bags produced by a company have the advantages of low temperature tolerance, safety, stability and high biocompatibility, which is very suitable for the current demand for pharmaceutical consumables in the field of biopharmaceuticals, especially in the hot field of cell therapy
.
epilogue
In general, supported by a series of favorable policies, the domestic biopharmaceutical market has developed rapidly, and the entire biopharmaceutical market has also continued to expand, according to Sullivan Consulting's forecast, the biopharmaceutical market is expected to reach 811.
6 billion yuan
in 2025.
In this context, the upstream pharmaceutical equipment industry is also expected to share dividends and undertake more benefits
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
